Handelsavisen
prelaunch
Companies Healthcare INDISA.SN
IN
INDISA.SN Santiago Healthcare Facilities & Services

Instituto de Diagnostico SA

$2 686,70
Open in Charts → Attach watcher ⌖
CLP
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
412,2B CLP
P/E
EV / Rev
Div yield
1,60 %
Op margin
12,9 %
ROE
7,6 %
Net margin
5,8 %
Debt / equity
0,48
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Instituto de Diagnostico SA provides diagnostic services and operates in the healthcare facilities and services industry, generating revenue primarily through its diagnostic operations.

Business. Instituto de Diagnostico SA (INDISA.SN) is a healthcare services and equipment company operating within the healthcare facilities and services industry. The firm generates service revenue and is headquartered in Chile, with its primary listing on the Santiago Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
7,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning INDISA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to INDISA.SN. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Instituto de Diagnostico SA (INDISA.SN) is a healthcare services and equipment company operating within the healthcare facilities and services industry. The firm generates service revenue and is headquartered in Chile, with its primary listing on the Santiago Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    Instituto de Diagnostico SA maintains a market price of 2700.0, with a market capitalization of 414,261,718,200.0. The company's price-to-earnings ratio is 26.45, and its price-to-book ratio is 2.0, indicating a moderate valuation relative to its book value. The enterprise value to EBITDA ratio is 14.26, and the enterprise value to revenue ratio is 1.83, suggesting a relatively low valuation in terms of revenue.

    The company's profitability is reflected in its return on equity of 7.56% and return on assets of 3.83%. These figures are compared against the industry's preferred metrics, indicating that the company is performing in line with or slightly below the median for its sector. The gross profit margin is 25.95%, and the operating margin is 12.85%, which are key indicators of the company's efficiency in converting revenue into profit.

    In terms of geographic and segment exposure, the company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. The company operates as a single segment, and its revenue is not diversified across multiple geographic regions. This concentration may pose a risk if the domestic market experiences economic downturns.

    The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current and next fiscal years. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on new assets. This suggests a conservative approach to capital spending and a focus on maintaining liquidity.

    The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flag of concern is the negative net cash position after subtracting total debt, which may affect the company's ability to meet short-term obligations. The company's debt-to-equity ratio is 0.48, and its current ratio is 1.18, indicating a moderate level of leverage and a relatively strong short-term liquidity position.

    Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company has not issued any new shares recently, and there are no indications of upcoming dilutive events. The company's financial statements and disclosures are consistent with its historical performance, and there are no material risks disclosed in recent filings.

    Key takeaways
    • Instituto de Diagnostico SA has a moderate valuation with a price-to-earnings ratio of 26.45 and a price-to-book ratio of 2.0.
    • The company's profitability is in line with industry standards, with a return on equity of 7.56% and a return on assets of 3.83%.
    • The company's revenue is primarily concentrated in its domestic market, with no significant international operations.
    • The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted.
    • The company has a medium level of liquidity risk and a low level of dilution risk.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $2 686,70
    Market cap
    $414.26B
    Enterprise value
    $499.12B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    19.6x
    P / B
    2.0x
    P / Tangible book
    2.0x
    Tangible book
    $207.27B
    Net cash
    -$84.86B
    Current ratio
    1.2
    Debt / equity
    0.5
    ROA
    3.8%
    ROE
    7.6%
    Cash conversion
    163.0%
    CapEx / revenue
    -1.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin12,8 %Above median
    Net Margin5,8 %Above median
    ROE7,6 %Above median
    Capex / Rev-1,4 %Above P75
    D/E0,48Below median
    Cash Conv1,63Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Instituto de Diagnostico SA Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    INDISA.SNCanonical
    Santiago · CLP

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage